AngioDynamics (ANGO) Rises 1.63% Despite Tariff Concerns

AngioDynamics (ANGO) shares rose 1.63% today, marking the lowest intraday decline of 2.56% since March 2025.

The strategy of purchasing ANGO shares upon reaching a recent low and holding for one week yielded moderate returns but underperformed the market. The annualized return of this strategy was approximately 5%, which is below the S&P 500's annualized return of 6.6% over the same period. This suggests that while the strategy provided some growth, it did not keep pace with broader market movements.

AngioDynamics' stock movements have been influenced by several recent factors. The company reported strong MedTech growth with a 12% revenue increase in Q4 Fiscal 2025. However, concerns about declining margins and future losses have led to a decline in stock price despite beating earnings expectations with an EPS of -$0.03 against the expected -$0.13.

The MedTech segment, particularly the Auryon platform, has shown significant growth, delivering its sixteenth consecutive quarter of double-digit increases. Mechanical thrombectomy products, AngioVac and AlphaVac, also reported substantial year-over-year growth.

Tariff expenses have impacted AngioDynamics' profitability, with $1.6 million in tariff expenses for Q4 2025. The company estimates that tariffs will continue to affect fiscal 2026, with expected costs of $4 to $6 million.

AngioDynamics has made progress with its MedTech portfolio, securing key regulatory approvals and expanding internationally. The company received CE Mark approval for Auryon in Europe, and the NanoKnife system gained an expanded indication for prostate tissue ablation, contributing to future revenue growth prospects.

Despite current financial challenges, the company maintains a Buy rating from several analysts, with price targets ranging from $16 to $17. This positive outlook is supported by AngioDynamics' strategic transformation into a MedTech-focused company.